BLCM Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The firm is primarily engaged in the research of cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases.

As of 05/12/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/18/2014
Outstanding shares:  8,318,273
Average volume:  159,959
Market cap:   $25,869,829
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    079481404
ISIN:        US0794814048
Sedol:      BKT71Q4
Valuation   (See tab for details)
PE ratio:   3.24
PB ratio:   12.26
PS ratio:   51.74
Return on equity:   1,061.47%
Net income %:   -5,301.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy